Dogs are man's best friend: in sickness and in health.

Abstract:

:With the median survival of 14.6 months following best available standard of care, malignant gliomas (MGs) remain one of the biggest therapeutic challenges of the modern time. Although the last several decades have witnessed tremendous advancement in our understanding of MG and evolution of many successful preclinical therapeutic strategies, even the most successful preclinical therapeutic strategies often fail to cross the phase I/II clinical trial threshold. One of the significant, but less commonly discussed, barriers in developing effective glioma therapy is the lack of a robust preclinical model. For the last 30 years, rodent orthotopic xenograft models have been extensively used in the preclinical setting. Although they provide a good basic model for understanding tumor biology, their value in successfully translating preclinical therapeutic triumph into clinical success is extremely poor. Companion dogs, which share the same environmental stress as their human counterparts, also spontaneously develop MGs. Dog gliomas that develop spontaneously in an immunocompetent host are very similar to human gliomas and potentially provide a stronger platform for validating the efficacy of therapeutic strategies proven successful in preclinical mouse models. Integrating this model can accelerate development of effective therapeutic options that will benefit both human subjects and pet dogs.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Bentley RT,Ahmed AU,Yanke AB,Cohen-Gadol AA,Dey M

doi

10.1093/neuonc/now109

subject

Has Abstract

pub_date

2017-03-01 00:00:00

pages

312-322

issue

3

eissn

1522-8517

issn

1523-5866

pii

now109

journal_volume

19

pub_type

杂志文章,评审
  • Functional analysis of a novel glioma antigen, EFTUD1.

    abstract:BACKGROUND:A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou132

    authors: Saito K,Iizuka Y,Ohta S,Takahashi S,Nakamura K,Saya H,Yoshida K,Kawakami Y,Toda M

    更新日期:2014-12-01 00:00:00

  • Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

    abstract:BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not068

    authors: de Blank PM,Berman JI,Liu GT,Roberts TP,Fisher MJ

    更新日期:2013-08-01 00:00:00

  • Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.

    abstract::In the present study we described the role of alpha9beta1 integrin in glioblastoma progression following its interaction with nerve growth factor (NGF). The level of expression of alpha9beta1 on astrocytomas is correlated with increased grade of this brain tumor and is highest on glioblastoma, whereas normal astrocyte...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-047

    authors: Brown MC,Staniszewska I,Lazarovici P,Tuszynski GP,Del Valle L,Marcinkiewicz C

    更新日期:2008-12-01 00:00:00

  • Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

    abstract::Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity. A total of 44 patients with glioblastoma with gros...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos003

    authors: Ulmer S,Spalek K,Nabavi A,Schultka S,Mehdorn HM,Kesari S,Dörner L

    更新日期:2012-04-01 00:00:00

  • Biology and management of ependymomas.

    abstract::Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now016

    authors: Wu J,Armstrong TS,Gilbert MR

    更新日期:2016-07-01 00:00:00

  • High failure rate in spinal ependymomas with long-term follow-up.

    abstract::Data on spinal ependymomas are sparse, and prognostic factors remain controversial. The primary aim of this study is to review a historical cohort, with large patient numbers and long follow-up, and provide estimates of time to progression (TTP) and survival after progression. As a secondary aim, we assess the effects...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/S1152851704001231

    authors: Gomez DR,Missett BT,Wara WM,Lamborn KR,Prados MD,Chang S,Berger MS,Haas-Kogan DA

    更新日期:2005-07-01 00:00:00

  • Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

    abstract:INTRODUCTION:Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos285

    authors: Alimova I,Birks DK,Harris PS,Knipstein JA,Venkataraman S,Marquez VE,Foreman NK,Vibhakar R

    更新日期:2013-02-01 00:00:00

  • DNA repair after irradiation in glioma cells and normal human astrocytes.

    abstract::We examined DNA damage responses and repair in four human glioma cell lines (A7, U87, T98G, and U373) and normal human astrocytes (NHAs) after clinically relevant radiation doses to establish whether we could identify differences among them that might suggest new approaches to selective radiosensitization. We used pho...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-030

    authors: Short SC,Martindale C,Bourne S,Brand G,Woodcock M,Johnston P

    更新日期:2007-10-01 00:00:00

  • On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

    abstract:BACKGROUND:Glioblastoma multiforme (GBM) is characterized by an aggressive clinical course, therapeutic resistance, and striking molecular heterogeneity. GBM-derived brain tumor stem cells (BTSCs) closely model this molecular heterogeneity and likely have a key role in tumor recurrence and therapeutic resistance. Emerg...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos302

    authors: Stechishin OD,Luchman HA,Ruan Y,Blough MD,Nguyen SA,Kelly JJ,Cairncross JG,Weiss S

    更新日期:2013-02-01 00:00:00

  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

    abstract::Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell coun...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-046

    authors: Heimberger AB,Sun W,Hussain SF,Dey M,Crutcher L,Aldape K,Gilbert M,Hassenbusch SJ,Sawaya R,Schmittling B,Archer GE,Mitchell DA,Bigner DD,Sampson JH

    更新日期:2008-02-01 00:00:00

  • Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

    abstract:Background:Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult patients with relapsed medulloblastoma (MB) to assess tumor response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox109

    authors: Kieran MW,Chisholm J,Casanova M,Brandes AA,Aerts I,Bouffet E,Bailey S,Leary S,MacDonald TJ,Mechinaud F,Cohen KJ,Riccardi R,Mason W,Hargrave D,Kalambakas S,Deshpande P,Tai F,Hurh E,Geoerger B

    更新日期:2017-10-19 00:00:00

  • Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling.

    abstract:BACKGROUND:Accumulation and infiltration of microglia/brain macrophages around and into glioma tissue promote tumor invasion and expansion. One tumor-promoting mechanism of microglia/brain macrophages is upregulation of membrane type 1 matrix metalloprotease (MT1-MMP), which promotes the degradation of extracellular ma...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou324

    authors: Hu F,Dzaye O,Hahn A,Yu Y,Scavetta RJ,Dittmar G,Kaczmarek AK,Dunning KR,Ricciardelli C,Rinnenthal JL,Heppner FL,Lehnardt S,Synowitz M,Wolf SA,Kettenmann H

    更新日期:2015-02-01 00:00:00

  • Brain metastases in melanoma: roles of neurotrophins.

    abstract::Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/s115285170300067x

    authors: Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

    更新日期:2004-04-01 00:00:00

  • Assessment and treatment relevance in elderly glioblastoma patients.

    abstract::Glioblastoma (GBM) is the most common malignant primary brain tumor. Its incidence continues to increase in the elderly because the older segment of the population is growing faster than any other age group. Most clinical studies exclude elderly patients, and "standards of care" do not exist for GBM patients aged >70 ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou063

    authors: Bauchet L,Zouaoui S,Darlix A,Menjot de Champfleur N,Ferreira E,Fabbro M,Kerr C,Taillandier L

    更新日期:2014-11-01 00:00:00

  • Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.

    abstract:BACKGROUND:The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz144

    authors: Nguyen TK,Sahgal A,Detsky J,Atenafu EG,Myrehaug S,Tseng CL,Husain Z,Heyn C,Maralani P,Ruschin M,Perry J,Soliman H

    更新日期:2020-01-11 00:00:00

  • Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.

    abstract:BACKGROUND:Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular s...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa117

    authors: Eckel-Passow JE,Drucker KL,Kollmeyer TM,Kosel ML,Decker PA,Molinaro AM,Rice T,Praska CE,Clark L,Caron A,Abyzov A,Batzler A,Song JS,Pekmezci M,Hansen HM,McCoy LS,Bracci PM,Wiemels J,Wiencke JK,Francis S,Burns TC,

    更新日期:2020-11-26 00:00:00

  • Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for gamma knife surgery planning.

    abstract::For gamma knife planning, 2.4-mm-slice MRIs are taken under rigid frame fixation, so tiny tumors become visible. This study evaluated differences in the numbers of brain metastases between conventional contrast-enhanced MRI (6 ± 1 mm slice thickness) taken before patient referral and contrast-enhanced MRI for gamma kn...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq084

    authors: Nagai A,Shibamoto Y,Mori Y,Hashizume C,Hagiwara M,Kobayashi T

    更新日期:2010-11-01 00:00:00

  • Diffuse midline glioma with an H3 K27M mutation: A comparison integrating the clinical, radiological, molecular features between adult and pediatric patients.

    abstract:BACKGROUND:Diffuse midline glioma (DMG), H3 K27M-mutant occurs in both adult and pediatric populations. The characteristics of the two DMG groups were systematically explored in this study. METHODS: One-hundred-sixteen patients diagnosed with H3 K27M-mutant DMG in Beijing Tiantan Hospital from May 2016 to December 201...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,收录出版

    doi:10.1093/neuonc/noz152

    authors: Jiang H,Yang K,Ren X,Cui Y,Li M,Lei Y,Lin S

    更新日期:2019-08-24 00:00:00

  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

    abstract:BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1093/neuonc/not049

    authors: Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

    更新日期:2013-07-01 00:00:00

  • High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.

    abstract::In patients with parenchymal brain masses of uncertain origin responsive to corticosteroids, primary CNS lymphoma (PCNSL) should be considered. PCNSL is a rare but aggressive brain tumor that is highly sensitive to high-dose methotrexate (HDMTX)-based chemotherapy. We report a series of six patients with brain masses ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-037

    authors: Kiewe P,Loddenkemper C,Anagnostopoulos I,Reinwald M,Thiel E,Korfel A

    更新日期:2007-04-01 00:00:00

  • New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

    abstract::Diffuse low-grade glioma grows, migrates along white matter tracts, and progresses to high-grade glioma. Rather than a "wait and see" policy, an aggressive attitude is now recommended, with early surgery as the first therapy. Intraoperative mapping, with maximal resection according to functional boundaries, is associa...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou153

    authors: Duffau H,Taillandier L

    更新日期:2015-03-01 00:00:00

  • Survey of treatment recommendations for anaplastic oligodendroglioma.

    abstract::Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by ex...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-002

    authors: Abrey LE,Louis DN,Paleologos N,Lassman AB,Raizer JJ,Mason W,Finlay J,MacDonald DR,DeAngelis LM,Cairncross JG,Oligodendroglioma Study Group.

    更新日期:2007-07-01 00:00:00

  • Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.

    abstract::Protein kinase C alpha (PKC-alpha) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation. Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice. In this ...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1215/S1152851703000353

    authors: Grossman SA,Alavi JB,Supko JG,Carson KA,Priet R,Dorr FA,Grundy JS,Holmlund JT

    更新日期:2005-01-01 00:00:00

  • An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013.

    abstract:BACKGROUND:Primary central nervous system tumors (PCNST) among adolescents and young adults (AYA, 15-39 y) have rarely been reported. We present a nationwide report of PCNST histologically confirmed in the French AYA population between 2008 and 2013. METHODS:Patients were identified through the French Brain Tumor Data...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz227

    authors: Ng S,Zouaoui S,Bessaoud F,Rigau V,Roux A,Darlix A,Bauchet F,Mathieu-Daudé H,Trétarre B,Figarella-Branger D,Pallud J,Frappaz D,Roujeau T,Bauchet L

    更新日期:2020-06-09 00:00:00

  • Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

    abstract:BACKGROUND:Glioblastomas with a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene have a better prognosis than gliomas with wild-type IDH1. METHODS:Here we compare the IDH1 mutational status in 172 contrast-enhancing glioma patients with the invasion profile generated by a patient-specific mathematical m...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou027

    authors: Baldock AL,Yagle K,Born DE,Ahn S,Trister AD,Neal M,Johnston SK,Bridge CA,Basanta D,Scott J,Malone H,Sonabend AM,Canoll P,Mrugala MM,Rockhill JK,Rockne RC,Swanson KR

    更新日期:2014-06-01 00:00:00

  • Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

    abstract:BACKGROUND:While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recu...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/nov145

    authors: Ringel F,Pape H,Sabel M,Krex D,Bock HC,Misch M,Weyerbrock A,Westermaier T,Senft C,Schucht P,Meyer B,Simon M,SN1 study group.

    更新日期:2016-01-01 00:00:00

  • A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

    abstract:BACKGROUND:Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective ope...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou126

    authors: de Jongste AH,van Gelder T,Bromberg JE,de Graaf MT,Gratama JW,Schreurs MW,Hooijkaas H,Sillevis Smitt PA

    更新日期:2015-01-01 00:00:00

  • The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

    abstract:BACKGROUND:Genetic and epigenetic profiling of glioblastomas has provided a comprehensive list of altered cancer genes of which only O(6)-methylguanine-methyltransferase (MGMT) methylation is used thus far as a predictive marker in a clinical setting. We investigated the prognostic significance of genetic and epigeneti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou005

    authors: Molenaar RJ,Verbaan D,Lamba S,Zanon C,Jeuken JW,Boots-Sprenger SH,Wesseling P,Hulsebos TJ,Troost D,van Tilborg AA,Leenstra S,Vandertop WP,Bardelli A,van Noorden CJ,Bleeker FE

    更新日期:2014-09-01 00:00:00

  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

    abstract::This study estimated the maximum tolerated dose (MTD) of imatinib with irradiation in children with newly diagnosed brainstem gliomas, and those with recurrent malignant intracranial gliomas, stratified according to use of enzyme-inducing anticonvulsant drugs (EIACDs). In the brainstem glioma stratum, imatinib was ini...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-031

    authors: Pollack IF,Jakacki RI,Blaney SM,Hancock ML,Kieran MW,Phillips P,Kun LE,Friedman H,Packer R,Banerjee A,Geyer JR,Goldman S,Poussaint TY,Krasin MJ,Wang Y,Hayes M,Murgo A,Weiner S,Boyett JM

    更新日期:2007-04-01 00:00:00

  • AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

    abstract::Neurofibromatosis type 2 (NF2) is an autosomal-dominant disease that results in the formation of bilateral vestibular schwannomas (VSs) and multiple meningiomas. Treatment options for NF2-associated tumors are limited, and to date, no medical therapies are FDA approved. The ideal chemotherapeutic agent would inhibit b...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor072

    authors: Bush ML,Oblinger J,Brendel V,Santarelli G,Huang J,Akhmametyeva EM,Burns SS,Wheeler J,Davis J,Yates CW,Chaudhury AR,Kulp S,Chen CS,Chang LS,Welling DB,Jacob A

    更新日期:2011-09-01 00:00:00